Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally.
3 contributing indexes 4 score components composite score.
Canonical asset packet first: fundamentals, macro index exposure, entry value, and active narrative alignment. Driver rows link back to the public index that moved the score.
| Index | Driver | Reason | Weight | Condition | Contribution | As Of |
|---|---|---|---|---|---|---|
| RQRI | Risk-Quality Rotation Index | risk appetite | 4% | risk appetite — tailwind Moderate signal—/100Tailwind +1.30σ | +0.040 | 2026-05-22 |
| RACI | Robotics & Automation Capex Index | research activity | 5% | research activity — tailwind Moderate signal—/100Tailwind +0.53σ | +0.034 | 2026-05-22 |
| BPHI | Biotech & Pharma Health Index | rare disease innovation | 17% | rare disease innovation — tailwind Near normal—/100Tailwind +0.13σ | +0.031 | 2026-05-22 |
